Ignite Creation Date:
2024-05-06 @ 2:20 PM
Last Modification Date:
2024-10-26 @ 1:29 PM
Study NCT ID:
NCT04286672
Status:
UNKNOWN
Last Update Posted:
2020-09-29
First Post:
2020-02-17
Brief Title:
Metadherin mRNA Expression in Bladder Cancer
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Serum Metadherin mRNA Expression in Bladder Cancer
Status:
UNKNOWN
Status Verified Date:
2020-08
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study aims to study alterations of MTDH gene expression in the serum of bladder cancer patients compared to control group to evaluate its role as a marker for diagnosis
to compare the diagnostic accuracy of MTDH with the previously used marker Bladder Cancer-Specific Antigen-1 BLCA-1 in the serum of bladder cancer patients
and to study correlation between expression of the metadherin gene and serum level of BLCA-1 and clinical and histopathological staging in patients with bladder cancer
to compare the diagnostic accuracy of MTDH with the previously used marker Bladder Cancer-Specific Antigen-1 BLCA-1 in the serum of bladder cancer patients
and to study correlation between expression of the metadherin gene and serum level of BLCA-1 and clinical and histopathological staging in patients with bladder cancer
Detailed Description:
Urinary bladder cancer BC is the ninth most common cancer worldwide It is the fifth most common malignancy in males and seventeenth most common in females
In Egypt bladder cancer represents a massive health burden where it is one of the commonest cancers representing 69 in both sexes and 107 among men Its distribution is 88 in lower Egypt 142 in middle Egypt and 126 in upper EgyptAlmost 50 of patients will experience recurrence of their disease within 4 years of their initial diagnosisThe prognosis of bladder cancer is poor as a result of highly invasive properties of tumour cells
The optimal treatment selection depends on early diagnosis as well as accurate staging and gradingCurrently there is a need for new molecular bio markers that can help clinicians to identify patients requiring early aggressive treatment
Metadherin MTDH is an oncogene known as Astrocytic elevated gene-1AEG-1It was firstly identified in 2002 at fetal astrocytes of persons exposed to HIV-1 and then known as a vital oncogene mediating carcinogenesisprognosisinvasion and cancer metastasis AEG-1 expression is raised in bladder cancer tissues relative to normal tissues and serves as a poor prognostic factor
In Egypt bladder cancer represents a massive health burden where it is one of the commonest cancers representing 69 in both sexes and 107 among men Its distribution is 88 in lower Egypt 142 in middle Egypt and 126 in upper EgyptAlmost 50 of patients will experience recurrence of their disease within 4 years of their initial diagnosisThe prognosis of bladder cancer is poor as a result of highly invasive properties of tumour cells
The optimal treatment selection depends on early diagnosis as well as accurate staging and gradingCurrently there is a need for new molecular bio markers that can help clinicians to identify patients requiring early aggressive treatment
Metadherin MTDH is an oncogene known as Astrocytic elevated gene-1AEG-1It was firstly identified in 2002 at fetal astrocytes of persons exposed to HIV-1 and then known as a vital oncogene mediating carcinogenesisprognosisinvasion and cancer metastasis AEG-1 expression is raised in bladder cancer tissues relative to normal tissues and serves as a poor prognostic factor
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None